New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis Novartis, 5 Jun 2013 Accessed on 8 Jun 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1707070.shtml. CommentRecommendBookmarkWatch